Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease. The company was founded in 1998 and is based in Austin, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PTIE
CUSIP69562K10
Phone512-501-2444
Debt
Debt-to-Equity RatioN/A
Current Ratio14.51
Quick Ratio14.51
Price-To-Earnings
Trailing P/E Ratio-1.21
Forward P/E Ratio-1.34
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.47 per share
Price / Book1.50
Profitability
EPS (Most Recent Fiscal Year)($1.82)
Net Income$-11,910,000.00
Net MarginsN/A
Return on Equity-101.55%
Return on Assets-93.41%
Miscellaneous
Employees9
Outstanding Shares6,900,000
Market Cap$15.38
Pain Therapeutics (NASDAQ:PTIE) Frequently Asked Questions
What is Pain Therapeutics' stock symbol?
Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."
When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work?
Shares of Pain Therapeutics reverse split on the morning of Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.
How were Pain Therapeutics' earnings last quarter?
Pain Therapeutics, Inc. (NASDAQ:PTIE) released its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.66) by $0.33. View Pain Therapeutics' Earnings History.
When is Pain Therapeutics' next earnings date?
What is the consensus analysts' recommendation for Pain Therapeutics?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pain Therapeutics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Pain Therapeutics' key competitors?
Some companies that are related to Pain Therapeutics include Evofem Biosciences (EVFM), Novus Therapeutics (NVUS), Zosano Pharma (ZSAN), Celsion (CLSN), IntelGenx Technologies (IGXT), Addex Pharmaceuticals (ADDXF), Imprimis Pharmaceuticals (IMMY), Heat Biologics (HTBX), vTv Therapeutics (VTVT), Moleculin Biotech (MBRX), Evoke Pharma (EVOK), AzurRx BioPharma (AZRX), Avenue Therapeutics (ATXI), Acerus Pharmaceuticals (TRLPF) and Capricor Therapeutics (CAPR).
Who are Pain Therapeutics' key executives?
Pain Therapeutics' management team includes the folowing people:
- Mr. Remi Barbier, Founder, Chairman, CEO, Pres & Principal Financial Officer (Age 58)
- Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 75)
- Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs
Has Pain Therapeutics been receiving favorable news coverage?
Media headlines about PTIE stock have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pain Therapeutics earned a media sentiment score of 0.17 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.94 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Pain Therapeutics?
Shares of PTIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pain Therapeutics' stock price today?
One share of PTIE stock can currently be purchased for approximately $2.21.
How big of a company is Pain Therapeutics?
Pain Therapeutics has a market capitalization of $15.38 million. The biopharmaceutical company earns $-11,910,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. Pain Therapeutics employs 9 workers across the globe.
How can I contact Pain Therapeutics?
Pain Therapeutics' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The biopharmaceutical company can be reached via phone at 512-501-2444.
MarketBeat Community Rating for Pain Therapeutics (NASDAQ PTIE)
MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe PTIE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTIE will underperform the S&P 500 over the long term. You may vote once every thirty days.
